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ABSTRACT: Antimicrobial resistance is a global healthcare problem with a
dwindling arsenal of usable drugs. Tuberculosis, caused by Mycobacterium
tuberculosis, requires long-term combination therapy and multi- and totally
drug resistant strains have emerged. This study reports the antibacterial
activity of cationic polymers against mycobacteria, which are distinguished
from other Gram-positive bacteria by their unique cell wall comprising a
covalently linked mycolic acid−arabinogalactan−peptidoglycan complex
(mAGP), interspersed with additional complex lipids which helps them
persist in their host. The present study ﬁnds that poly(dimethylaminoethyl
methacrylate) has particularly potent antimycobacterial activity and high
selectivity over two Gram-negative strains. Removal of the backbone methyl
group (poly(dimethylaminoethyl acrylate)) decreased antimycobacterial
activity, and poly(aminoethyl methacrylate) also had no activity against
mycobacteria. Hemolysis assays revealed poly(dimethylaminoethyl methacry-
late) did not disrupt red blood cell membranes. Interestingly, poly(dimethylaminoethyl methacrylate) was not found to
permeabilize mycobacterial membranes, as judged by dye exclusion assays, suggesting the mode of action is not simple
membrane disruption, supported by electron microscopy analysis. These results demonstrate that synthetic polycations, with the
correctly tuned structure are useful tools against mycobacterial infections, for which new drugs are urgently required.
■ INTRODUCTION
The emergence and spread of antimicrobial resistance (AMR)
is a rapidly growing, global, healthcare threat. There have been
no new classes of antibiotics since 1987 with the pipeline of
new antibiotics being scarce.1 Each year in the United States, at
least 2 million people become infected with bacteria that are
resistant to antibiotics and at least 23 000 people die each year
as a direct result of these infections.2 Estimates of the cost of
antibiotic-resistant infections in the United States alone are US
$ 21 billion to US$ 34 billion3 needing a rethink of the
approach to tackle this threat.4 New and innovative treatments
and diagnostics are urgently required.5−9A re-emerging threat is
multi- and totally drug resistant Mycobacterium tuberculosis
(Mtb), the causative agent of tuberculosis (TB). It is estimated
that there are up to 2 billion latent infections globally (with
London known as the TB capital of Europe10), and it is now
found in wealthy countries where it had previously been
eradicated. In 2014 alone, there were about 480 000 new cases
of multidrug-resistant Mtb (MDR-TB). Extensively drug-
resistant Mtb (XDR-TB) has been identiﬁed in 100 countries.11
The slow growth rate of Mtb and complex lipid-rich cell wall
contribute to its persistence inside host organisms and there are
few new candidate drugs against it.12,13 To counter the threat of
AMR, new and innovative approaches to drug design are
needed, which might not be limited to the “small molecule-
single target” paradigm or strict adherence to Lipinski’s rules of
small hydrophobic drugs.14 An interesting class of antimicro-
bials are cationic antimicrobial peptides (CAMPS).15−17
CAMPS are thought to function by interaction with the
anionic bacterial cell membrane followed by cell wall
permeabilization, or pore formation which ultimately leads to
cell death, although the exact mechanisms are not fully
understood and are under debate.18,19 Examples of CAMPS
include the peptide Nisin which is widely used in the dairy
industry as an antibiotic20 and Colistin a (polymyxin cyclic
peptide with a hydrophobic tail) which is an antibiotic of last
resort for infections such as Pseudomonas aeruginosa but its use
is limited by its high toxicity. The biocompatibility of CAMPS
is a key issue as they can also disrupt the anionic membrane of
eukaryotic (mammalian) cells, particularly red blood cells
(RBCs). Reduction of the net cationic charge mitigates toxicity
but reduces activity meaning a precise balance must be
maintained.21
In an eﬀort to create synthetic mimics of antimicrobial
peptides (SMAMPS), cationic polymers have emerged as an
easy-access class of antibacterial materials which have been
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extensively reviewed.22−25 Synthetic polymers are particular
appealing as their composition and architecture can be ﬁnely
tuned using controlled (e.g., radical or ring-opening) polymer-
ization methods and a huge range of monomers are available.
These have been widely incorporated as biocidal coatings26 or
as mediators of bacteria aggregation and signaling which can
eﬀect quorum sensing as well as killing.27 Fernandez-Trillo and
co-workers recently demonstrated that polyionic complexes of
an antibacterial polymer with an anionic peptide which upon
exposure to elastase secreted by P. aeruginosa released the
polymer leading to antibacterial activity, as a new route to
targeted antimicrobials.28
The mechanism of the membrane disrupting polycations, is
thought to make resistance less likely to develop as there is no
single protein target. Cationic, second generation PAMAM
(poly(amidoamine)) dendrimers have been reported to not
induce resistance in penicillin resistant Escherichia coli and
methicillin-resistant Staphylococcus aureus.29 In contrast, CAMP
resistance through neutralization of anionic surface charges or
changes in eﬄux pumps have been found, indicating that
resistance is possible and that the mechanism of action varies
between polycations.30,31 Ikeda et al. found that molecular
weight of the polycations was crucial. Using cationic
polyacrylates, it was found that a molecular weight of 5−10
kDa was optimal with shorter or longer polymers leading to a
decrease in antimicrobial activity against S. aureus.32 Bacterial
clustering triggered by polycations has recently been found to
play a complex role in cell signaling beyond their cell lytic
behavior also.33 Generally, Gram-negative bacterial membranes
are harder to disrupt than Gram-positive due to the presence of
an inner and outer membrane structure, which limits the action
of simple polycations. However, Tew et al. have developed a
range of facially amphiphilic polymers, which reproduce the
cationic/lipophilic character of natural CAMPs such as
magainins which are broad spectrum antimicrobials.34
Considerable eﬀect has been placed on the development of
cationic polymers for Gram-negative bacteria due to their
widespread role in human disease. Gram-positive bacteria and
the Mycobacterium genus, including Mtb, have been less studied
in the context of polymer antimicrobials. The double versus
single membrane cell wall structure between Gram-negative
and Gram-positive (respectively) results in vastly diﬀerent
susceptibility to cationic polymers.35 The cell wall components
of Gram-positive and mycobacteria equally display vastly
diﬀerent components, with mycobacteria having a distinct
mAGP cell wall complex, rich in complex lipids and
carbohydrates. Synthetic CAMPS with just 10 amino acids
have been found to be active against Mtb at 10 μM
concentrations36 as have naturally occurring anti-TB peptides
from several kingdoms of life.37 Synergistic anti-Mtb activity
was seen with CAMPS in combination with the front line drug
rifampicin, potentially due to the CAMPS disrupting the
membrane to promote drug uptake.38 It has also been found
that antimicrobial peptides attach to teichoic acids in cell wall of
Gram-positives (which are not present in mycobacteria) and
not the anionic cell membrane supporting the concept that the
design rules to target mycobacteria will be signiﬁcantly diﬀerent
for that of Gram-negative and Gram-positive organisms.39 Tew
and co-workers showed that facially amphiphilic SMAMPS
were broad spectrum Gram-negative/positive active, but
disruption of this amphiphilicity results in only maintaining
activity against Gram-positives (S. aureus) again suggesting that
a simplicity driven approach toward antituberculars might be
possible.40
Considering the above observations, it would seem that the
development of new synthetic materials that can selectively
target mycobacteria is possible, especially as other Gram-
positive strains seem particularly susceptible. This study reports
a preliminary investigation into the use of RAFT-derived
(reversible addition−fragmentation chain transfer) synthetic
cationic polymers against mycobacteria, which may enable
them to be used as a new tool for treating such infections.
Poly(dimethylaminoethyl methacrylate) in particular is shown
to have potent, and selective activity against mycobacteria
relative to Gram-negative strains.
■ EXPERIMENTAL SECTION
Materials. 4-Cyano-4-(phenylcarbonothioylthio)pentanoic acid
(>97.0%), 4,4′-azobis(4-cyanovaleric acid) (≥98.0%), mesitylene
(analytical standard), 2-mercaptoethanol (≥99.0%), tribasic potassium
phosphate (reagent grade, ≥98.0%), carbon disulﬁde (≥99.0%), and
benzyl bromide (98.0%) were purchased from Sigma-Aldrich.
Monomers were purchased from Sigma-Aldrich and inhibitors
removed by passing through a column of basic alumina prior to
polymerization. RAFT agents were prepared as previously described.45
Physical and Analytical Methods. SEC analysis was performed
using a Varian 390-LC MDS system equipped with a PL-AS RT/MT
autosampler, a PL-gel 3 μm (50 × 7.5 mm) guard column, two PL-gel
5 μm (300 × 7.5 mm) mixed-D columns using DMF with 5 mM
NH4BF4 at 50 °C as eluent at a ﬂow rate of 1.0 mL.min
−1. The SEC
system was equipped with ultraviolet (UV)/visible (set at 280 and 461
nm) and diﬀerential refractive index (DRI) detectors. Narrow
molecular weight PMMA standard (200−1.0 × 106 g mol−1) were
used for calibration using a second order polynomial ﬁt. NMR
spectroscopy (1H, 13C) was conducted on a Bruker DPX-300, Bruker
DRX-500 or Bruker AV III 600 spectrometer using deuterated
chloroform or deuterated methanol as solvent. All chemical shifts are
reported in ppm (δ) relative to the solvent used. FTIR spectra were
acquired using a Bruker Vector 22 FTIR spectrometer with a Golden
Gate diamond attenuated total reﬂection cell. A total of 64 scans were
collected on samples in their native state. Microscopy was performed
using a Zeiss LSM 880 microscope. SYTO-9 dye was imaged by
excitation at 488 nm and emission at 530 nm for green ﬂuorescence.
Propidium iodide was imaged by excitation at 561 nm and emission at
646 nm for red ﬂuorescence.
Synthetic Section. Polymerization of Dimethylaminoethyl
Methacrylate. Dimethylaminoethyl methacrylate (2.00 g, 12.7
mmol), 2-cyano-2-propyl dodecyl trithiocarbonate (87.9 mg, 255
μmol), and azobis(isobutyronitrile) (4.18 mg, 25.5 μmol) were
dissolved in dioxane (2 mL) in a glass vial containing a stir bar. The
mixture was added to a dry ampule under a N2 atmosphere and
degassed by three freeze−pump−thaw cycles. The reaction mixture
was stirred and heated by an oil bath thermostated at 65 °C. After 6 h,
the reaction mixture was opened to air and quenched in liquid
nitrogen. An aliquot was removed and conversion determined by 1H
NMR spectroscopic analysis. The product was puriﬁed by dialysis into
deionized water (MWCO = 1000 g·mol−1). The solid was isolated by
lyophilization to give a waxy, yellow solid. Conversion (NMR): 51.9%;
Mn (theoretical): 4100 g·mol
−1; Mn (SEC) 11 000 g·mol
−1; Mw/Mn
(SEC): 1.25.
Polymerization of Aminoethyl Methacrylate Hydrochloride. 2-
Aminoethyl methacrylate hydrochloride (0.83 g, 5.01 mmol), 4-cyano-
4-(phenylcarbonothioylthio)pentanoic acid (3.50 mg, 12.53 μmol)
and 4,4′-azobis(4-cyanovaleric acid) (3.57 mg, 12.72 μmol) were
dissolved in 0.6 mL of acetate buﬀer at pH 5.2 (produced using 0.27
mol·L−1 acetic acid and 0.73 mol·L−1 sodium acetate) in a 50 mL
round bottomed ﬂask, from a stock solution and subsequently diluted
to 5 mL with the addition of further acetate buﬀer. The ﬂask was
purged with nitrogen for 45 min and placed in an oil bath at 70 °C.
After 180 min the reaction was quenched using liquid nitrogen.
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Dialysis using acetate buﬀer (24 h, 5 water changes) and lyophilization
were then used to purify the product. 1H NMR (D2O): δ 4.21 (br, 2H,
−OCH2); δ 3.31 (br, 2H, −NH2CH2); δ 1.95 (br, 2H, backbone
CH2); δ 0.83−1.36 (br, 3H, backbone CH3).
Polymerization of Dimethylaminoethyl Acrylate. Dimethylami-
noethyl acrylate (1.00 g, 6.98 mmol), 2-(dodecylthiocarbonothioylth-
io)-2-methylpropanoic acid (25.47 g, 69.80 μmol) and 4,4′-azobis(4-
cyanovaleric acid) (3.92 mg, 14.00 μmol) were dissolved in dioxane (4
mL) in a glass vial containing a stir bar. Mesitylene (200 μL) was
added as an internal reference and the mixture stirred (5 min). An
aliquot of this starting mixture was removed for 1H NMR
spectroscopic analysis. The vial was ﬁtted with a rubber septum and
degassed by bubbling with nitrogen gas (30 min). The vial was then
placed in an oil bath thermostated at 70 °C. After 6 h, the reaction
mixture was opened to air and quenched in liquid nitrogen. An aliquot
was removed and conversion determined by 1H NMR spectroscopic
analysis. The product was puriﬁed three times by precipitation from
tetrahydrofuran into hexane, isolated by centrifugation and dried under
vacuum overnight to give a waxy, yellow solid. Conversion (NMR):
77.6%; Mn (theoretical): 11 000 g·mol
−1; Mn (SEC) 6900 g·mol
−1;
Mw/Mn (SEC): 1.43.
Microbiology Section. Bacterial Strains and Growth Con-
ditions. Mycobacterium smegmatis MC2155 was grown in either Tryptic
Soy broth with the addition 0.05% Tween 80 (TSBT) or Middlebrook
7H9 media supplemented with 0.2% glycerol and 0.05% Tween 80.
Escherichia coli Top10 and Pseudomonas putida KT4224 were grown in
Luria−Bertani (LB) media.
Determination of Antibacterial Activities of Compounds 1−6.
Minimum inhibitory concentrations (MICs) of the compounds were
determined against M. smegmatis, P. putida, and E. coli. The bacteria
were cultured to mid log phase and the inoculum standardized to 1 ×
105 CFU·mL−1 before addition to a 96-well microtiter plate in which
P1−6 were serially diluted 2-fold across the plate. Control wells
containing culture controls and a reference drug were undertaken. In
the case of M. smegmatis rifampicin was used, for E. coli ampicillin was
used and for P. putida tetracycline was used. The plates were incubated
at 37 °C for 72 h for M. smegmatis, at 37 °C for 18 h for E. coli and at
30 °C for 18 h for P. putida. Following this incubation period 25 μL
resazurin was added (one resazurin tablet (VWR) in 30 mL sterile
PBS) and left for a further incubation period (24 h for M. smegmatis, 4
h for E. coli and P. putida. The MIC values were determined as the
lowest concentration of drug concentration that prevented the color
change of resazurin (blue, no bacterial growth) to resoruﬁn (pink,
bacterial growth). The MIC values were determined in triplicate.
Minimal Bactericidal Concentration (MBC) Determination.
Minimal bactericidal concentrations (MBCs) against replicating M.
smegmatis were determined. M. smegmatis (inoculum of 105 CFU·
mL−1) was cultured in the presence of P1−3 in a 96-well microtiter
plate for 24 h at 37 °C. The highest concentrations of P1−3 were
equivalent to a ﬁnal concentration of 10 × MIC in the ﬁrst wells and
this was serially diluted 2-fold across the plate. Following incubation in
the presence of compounds P1−3, 100 μL of the cells from each well
were plated onto LB agar and incubated at 37 °C for 72 h. After 72 h
the colonies on each plate were counted and the MBC determined to
be the lowest concentration of the compound that resulted in the
observation of no growth of M. smegmatis. The MBC values were
determined in triplicate.
Time Kill Assays. Cultures of M. smegmatis (inoculum of 105 CFU·
mL−1) were incubated with 2× MBC P3 (62.5 μg·mL−1) and 2 ×
MBC Rifampicin (6.25 μg·mL−1) in 7H9 broth at 37 °C. At deﬁned
intervals (0, 1, 2, 3, 4, 6, 24, and 48 h), 100 μL of each culture was
plated onto LB agar containing no antibiotics and incubated at 37 °C
for 2 days. Cell viability was assessed by determining CFU·mL−1
values. Each assay was performed in triplicate.
Confocal Microscopy. M. smegmatis was grown to late log phase
before being harvested by centrifugation at 3300g for 15 min. The cell
pellet was resuspended in 0.85% NaCl, then aliquoted and incubated
with 0.5× MBC (15.625 μg·mL−1) and 2 × MBC (62.5 μg·mL−1) P3,
0.5 × MBC (62.5 μg·mL−1) and 2 × MBC (250 μg·mL−1) P4 for 15
min at room temperature. A single aliquot was used as a live cells
control incubated with no drug and a further aliquot was used as a heat
killed cells control, incubated at 80 °C for 30 min. After incubation, all
samples were washed with 0.85% NaCl twice, with the suspension
volume halved the second time. A Live/Dead BacLight bacterial
viability kit (Invitrogen) was used to check cell viability. Brieﬂy, Dye A
(Syto-9) and Dye B (propidium iodide) were used in a 1:1 ratio and
added to all samples before incubation for 15 min in the dark. Samples
were then analyzed using a Zeiss LSM 880 confocal microscope to
check for green (Ex 488 nm Em 520 nm) and red (Ex 561 nm, Em
646 nm) ﬂuorescence.
Scheme 1. RAFT Polymerization to Generate Cationic Polymersa
aConditions are shown in Table 1.
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Hemolysis Assay. Samples containing 250 μL ovine red blood
cells (RBCs) and 250 μL of polymer solution (at indicated
concentration) were incubated at 37 °C for 1 h. After centrifugation,
10 μL of the supernatant was added to 90 μL of PBS buﬀer in a 96 well
plate. The absorbance was measured at 450 nm and compared against
a PBS buﬀer and deionized water (to lyse cells) controls to determine
the % hemolysis.
Transmission Electron Microscopy (TEM). Transmission
electron microscopy (TEM) was performed as previously described.46
Brieﬂy, M. smegmatis was cultured in TBST for 72 h at 37 °C, 200 rpm.
The culture was then diluted 1/100 in fresh TBST media and P1 was
added to the culture to give a ﬁnal concentration of P1 of 0.5 × MIC99.
The culture was incubated for 18 h at 37 °C, 200 rpm. The cells were
then centrifuged at 2400g for 10 min. The cell pellets were
resuspended in 1× PBS and centrifuged and resuspended in 1× PBS
twice more. The cell pellets were then ﬁxed and processed as described
previously.46 Samples were ﬁxed in 2% glutaraldehyde washed in 3×
PBS, then ﬁxed with 2% osmium tetroxide with ruthenium red,
washed, dehydrated through an ethanol gradient, proplylene oxide
then low viscocity epoxy resin. Polymerized at 60 °C overnight and
sectioned on a UltracutE ultramicrotome at 80 nm, stained with 2%
uranyl acetate and Reynolds Lead Citrate before imaging. TEM
imaging was carried out on a JEOL 2200FS at 200 kV using a Gatan
K2 summit camera.
■ RESULTS AND DISCUSSION
To evaluate if cationic polymers are potential lead candidates
against mycobacteria, with a unique cell wall distinct from that
of Gram-positive and Gram-negative organisms, a small panel
of cationic polymers was selected, based on commercially
available monomers. To this end, DMAEMA (dimethylami-
noethyl methacrylate), DMAEA (dimethylaminoethyl acrylate),
and AEAM (aminoethyl acrylate) were chosen based on
previous reports on their antimicrobial activity and the
commercial availability of the starting monomers.41 To ensure
control over polymer molecular weight and dispersity, RAFT
polymerization was employed, Scheme 1, using the indicated
chain transfer agents (CTAs).
DMAEMA and DMAEA were polymerized in dioxane, and
AEMA in acetate buﬀer (pH 5.2) to ensure protonation of the
primary amine, which could otherwise undergo side reactions
with the RAFT agent/ester group.42 Following polymerization,
the polymers were isolated by precipitation and dialyzed against
Milli-Q water to remove excess monomer/solvent. The
resulting polymers were characterized by SEC (size exclusion
chromatography) and NMR spectroscopy, Figure 1 and Table
1. SEC analysis revealed monomodal distributions but higher
than expected dispersity values, which could be attributed to
column interactions, as is common for amino-containing
polymers. The amine side chains could also lead to some
reduction in the ﬁdelity of the RAFT agent also, leading to
broadening. Nonetheless, these are accep for the purposes of
this study (vide infra) where a library of diﬀerent chain lengths
was the target. The SEC molecular weights were also larger
than expected from conversion and the feed ratio, supporting
the assumption of some column interactions. PAEMA is
challenging to characterize by SEC, as we have previously
reported meaning only an estimated Mn based on conversion
and the [monomer]:[CTA] feed ratio.42
This focused library of polymers was then used to screen for
antibacterial activity. Three representative strains of bacteria
were chosen for this: Escherichia coli, a Gram-negative bacteria;
Pseudomonas putida, which is a Gram-negative bacteria closely
related to pathogenic pseudomonas strains; and Mycobacterium
smegmatis, from the Mycobacterium genus, and an avirulent
model organism for Mtb.12 The minimum inhibitory concen-
trations (MIC) of the polymer library was determined against
all the bacteria using a resazurin microtiter viability assay. In
short, the polymers were serially diluted, added to the bacterial
cultures, and the concentration where growth was inhibited
reported as the MIC99 value. All assays were carried out in
triplicate and the results of this are shown in Table 2.
Due to the presence of the inner and outer cell membranes,
Gram-negative bacteria are challenging to kill using polycations,
requiring careful installation of hydrophobic groups to promote
insertion and disruption of the inner/outer membranes, or in
the case of PDMAEMA a reduction in pH to increase the net
positive charge (the aim here was to test at physiological pH
hence it was maintained at 7.4). Our results were in agreement
with this hypothesis, with all polymers having higher MIC99
values against P. putida and E. coli than against M. smegmatis. In
the case of P5 and P6, extremely high concentrations were
needed (concentrations above 3125 μg·mL−1, Table 2) despite
the only structural diﬀerence compared to P1−3 being the
absence of the backbone methyl group (Scheme 1). These
subtle eﬀects highlight the challenge of designing potent
macromolecular antimicrobials as each individual strain has
subtly diﬀerent membrane components that govern the initial
interactions, but also may oﬀer a route to selectivity. Of
particular interest was that P1−3 were very active against M.
smegmatis, with the MIC99 value only 5× higher than that of
rifampicin (on a mass basis, more active on molar due to high
MW of polymers), a front-line antibiotic used against
mycobacteria. The observed potency is similar to what has
been reported for other antimicrobial polymers against
nonmycobacteria, such as degradable polycarbonates25 or
amino-terminated dendrimers with in vivo activity against E.
coli infections in mice.29 The activity of these polymers is
somewhat surprisingly considering the complex mAGP
Figure 1. SEC analysis of polymers used in this study, as shown in
Table 1.
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complex that surrounds mycobacteria, which would be expected
to reduce the electrostatic interactions between polycations and
the anionic cell membrane components. Against M. smegmatis,
there was no clear eﬀect of molecular weight on activity, but
against the Gram-negative organisms, the shortest (4500 g·
mol−1) polymers (P1) showed increased activity (Table 2).
This is in line with observations by Ikeda et al., who saw that
molecular weight eﬀects on antimicrobial polycations were
most pronounced below 10 kg mol−1.32
Based on their selectivity toward M. smegmatis the
PDMAEMAs (P1−3) were further tested to determine their
minimum bactericidal concentration (MBC). Brieﬂy, the
bacteria were grown in the presence of serial dilutions of
P1−3 starting from 10× MIC99 and after 24 h plated on solid
agar media and counted. The minimum concentration required
to kill all the bacteria was reported, Table 3. Pleasingly, these
values were found to closely correlate with those from the
resazurin MIC testing in liquid media, conﬁrming the
bactericidal activity of the polymers. There was some evidence
that P1 (lowest Mn) had slightly higher activity than the longer
P2 and P3 which agrees with the observations from the MIC99
results (from Table 2, above). P3 was also tested in a time-kill
assay at 2× MBC and compared to the front-line drug
rifampicin (also at 2× MBC), to determine the rate of
antibacterial action against M. smegmatis, Figure 2. The polymer
killed all the bacteria (down to the detection limit of the assay)
within 6 h, but rifampicin took 48 h. This highlights the potent
nature of PDMAEMA against mycobacteria, which functions by
a mechanism distinct (vide infra) from front-line drugs, which
are slow to act, as they disrupt physiological pathways, which
are themselves slow due to the slow-growing nature of
mycobacteria.
Previous reports of PDMAEMA against Gram-positive
bacteria (not mycobacteria) suggested that the mode of action
involved membrane binding, followed by permeabilization of
the cell membrane, enabling leakage of cytoplasmic contents.41
This is also a potential route to cytotoxicity through lysis of
mammalian cell membranes. In particular, this is an issue for
red blood cells (RBCs) a key clinical side-eﬀect in the ﬁeld of
antimicrobial polymers/peptides. P2−4 were tested up to 5
mg·mL−1 at 37 °C against (ovine) RBCs (Figure 3). P2 and P3,
which were active against M. smegmatis, showed very little
hemolysis, below 2% even at the highest concentration tested as
would be expected for this polymer.43 Higher concentrations of
PDMAEMA (>100 μg·mL−1) and molecular weights above 20
kDa than used here have been reported to lead to RBC
agglutination, but was not seen here.43 In contrast, P4 with a
Table 1. Cationic Polymers Synthesized by RAFT Polymerization
polymer monomer [M]:[CTA] conversion (%)a Mn(th) (g mol
‑1)b Mn(SEC) (g mol
‑1) Mw/Mn
c
P1 DMAEMA 50 51.9 4500 11 000 1.25
P2 DMAEMA 50 77.3 6100 13 900 1.61
P3 DMAEMA 100 71.4 11 200 21 800 1.64
P4 AEMA 100 71.4 11 200 N/A N/A
P5 DMAEA 100 77.6 11 000 6900 1.43
P6 DMAEA 25 89.6 3200 3300 1.47
aDetermined by 1H NMR against an internal mesitylene standard. bDetermined by the [M]:[CTA] ratio and conversion, assuming 100% CTA
eﬃciency. cDetermined by SEC against PMMA standards.
Table 2. Minimum Inhibitory Concentrations of Polymers P1−6a
polymer M. smegmatis (Mycobacteria) (μg·mL−1) P. putida (Gram-negative) (μg·mL−1) E. coli (Gram-negative) (μg·mL−1)
P1 31.25 156.25 62.5
P2 31.25 >5000 250
P3 31.25 >5000 250
P4 500 625 1000
P5 >5000 >5000 >5000
P6 3125 >5000 >5000
tetracycline × 156.25 ×
rifampicin 6.25 × ×
ampicillin × × 3.125
aAll values from three repeats; × indicates the antibiotic was not used against that strain. Antibiotics chosen based on their front-line use against
associated infections.
Table 3. Minimum Bactericidal Concentration of P1−3
against M. smegmatis
polymer μg·mL−1
P1 31.25
P2 31.25−62.5
P3 31.25−62.5
Figure 2. Time-kill assay of P3 against M. smegmatis. Errors bars
represent the standard deviation from n = 3.
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primary amine group showed signiﬁcant hemolysis at all
concentrations. These results show that the identiﬁed
PDMAEMA are more selective toward mycobacteria and less
hemolytic than the primary amine containing polymers. (It
should be noted that this does not necessarily indicate a
complete lack of cytotoxicity44).
The lack of activity against RBCs even at high concentrations
raises questions about the mechanism of action against bacteria.
Tew and co-workers have extensively studied the mechanism of
facially amphiphilic cations against Gram-negative bacteria,
revealing a complex process which appears to involve the
formation of pores in the membrane enabling leaking of cellular
components.19 To probe the nature of the polymer−bacteria
interaction the polymers were evaluated for their ability to
permeabilize membranes using ﬂuorescence microscopy in
conjugation with membrane permeable/imperable dyes (“live/
dead”), Figure 4. Control experiments of live M. smegmatis
show green color due to the SYTO 9 dye associated with live
(membrane intact) bacteria. Conversely, heat killed M.
smegmatis (which does not lyse the bacteria) showed no
green color but some were red, indicative of propidium iodide
(dye) being able to cross damage cell membranes. Incubation
of the M. smegmatis with P3 (PDMEAMA) for 30 min (as this
eﬀect would be direct and rapid and avoiding secondary
interactions which could be mistaken for membrane damage
and hence longer periods were not used, and guided by the kill-
curve in Figure 2) both above (2× MIC) and below (0.5×
MIC) MIC99 values resulted in green colored bacteria being
obtained in both cases. As the assay does not actually probe if
they are alive, but rather if the membrane is damaged, this
result suggested that PDMAEMA does not immediately
damage the cell membrane, in contrast to the expected mode
of action of a polycation. P4 (PAEMA) with a primary amine
side chain, resulted in red bacteria, due to extensive damage to
the cell membrane, consistent with how other polycations
function, and suggesting a unique mode of action between
PDMAEMA and mycobacteria.
PDMAEMA (P1−3) was the most active polymer class
against mycobacteria, with high selectivity toward these
compared to Gram-negative bacteria and erythrocytes while
also having relatively low membrane lytic activity. These assays
do not, however, prove the lack of interaction/impact between
the polymers and the bacterial membranes, just that they are
intact and resistant to permeation. To visualize the impact on
the membrane, transmission electron microscopy (TEM) was
conducted on M. smegmatis, which was grown with and without
the polymers at sublethal doses at 0.5 × MIC99, Figure 5. After
incubation, the bacteria were ﬁxed, stained and imaged. The
wild type M. smegmatis without the polymer showed the
expected cell morphology and membrane structure indicating it
was intact when ﬁxed. However, the M. smegmatis incubated
with P1 clearly showed signs of distress, with signiﬁcant signs of
puckering strongly suggesting that the cell wall has been
stressed. A possible explanation for this observation would be
electrostatic interactions between the polymer and the unique
mycobacterial cell wall lipids and/or anionic cell membranes.
Nonetheless, these images clearly support a mechanism based
on cell wall surface interactions of the polymer.
■ CONCLUSIONS
Here it is demonstrated that poly(dimethylaminoethyl
methacrylate), PDMAEMA, has potent and selective anti-
mycobacterial activity against a model strain for M. tuberculosis.
Conversely, it was weakly active against two Gram-negative
strains, indicating selectivity. Relatively low molecular weight
PDMAEMA (11 kDa) was shown to have minimum inhibitory
values as low as 30 μg·mL−1. An acrylate equivalent and
polymers with primary amine side chains were found to be
signiﬁcantly less active. Mechanistic studies revealed that the
PDMAEMA did not aﬀect the integrity of the mycobacterial
cell membrane, conﬁrmed by ﬂuorescent microscopy, indicat-
Figure 3. Assessment of hemolytic activity of polymers P2−4 after 1 h
of exposure against ovine red blood cells. Error bars represent the
standard deviation n = 3.
Figure 4. Fluorescence microscopy of M. smegmatis upon exposure to
varying concentrations of P3 and P4. Green channel is SYTO-9
(nucleic acid stain), and red is propidium iodide (damage membrane
stain). Each image is 85 × 85 μm2.
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ing an intact membrane/cell wall, unlike primary amine-
containing polymers, which despite having lower activity clearly
disrupted the cell membranes. TEM analysis supported a
mechanism where the PDMAEMA is binding to, and aﬀecting
the outer-cell components but without causing lysis. Finally,
PDMAEMA was shown to be nonhemolytic to red blood cells,
conﬁrming that it has a unique mode of action in exerting its
eﬀect on mycobacteria as well as demonstrating some
biocompatibility. The underlying reasons for the selectivity
toward mycobacteria, compared to Gram-negative strains is not
clear at this time but could be due to the unique mAGP
complex layer surrounding mycobacteria, which are rich in
anionic mycolic acids and interspersed with complex lipids that
are not found in Gram-negative (or Gram-positive) organisms.
Taken together, this shows that nontraditional antibiotics which
target bacterial extracellular components, rather than traditional
single drug/single protein drugs might oﬀer a solution to the
emergence of multidrug resistant mycobacteria and that
(relatively) simple polycations could supplement the arsenal
of antimycobacterial drugs, in particular against M. tuberculosis
which is a devastating global disease.
■ AUTHOR INFORMATION
Corresponding Authors
*Fax: +44 247 652 4112. E-mail: m.i.gibson@warwick.ac.uk.
*Fax: +44 247 652 2052. E-mail: e.fullam@warwick.ac.uk.
ORCID
Matthew I. Gibson: 0000-0002-8297-1278
Notes
The authors declare no competing ﬁnancial interest.
■ ACKNOWLEDGMENTS
Equipment used was supported by the Innovative Uses for
Advanced Materials in the Modern World (AM2), with support
from Advantage West Midlands (AWM) and part funded by
the European Regional Development Fund (ERDF). The
microscopy imaging facilities are funded by University of
Warwick Advanced BioImaging Research Technology Platform
and BBSRC ALERT14 award BB/M01228X/1. The Royal
Society provided funds for the plate reader (Grant number
RG120405). M.I.G. acknowledges the ERC for a starter grant
(CRYOMAT 638661). E.F. has a Sir Henry Dale Fellowship
jointly funded by the Wellcome Trust and the Royal Society
(Grant Number 104193/Z/14/Z). D.E.M. thanks the MOAC
DTC for a Ph.D. studentship EP/F500378/1. D.P. and S.-J.R.
thank the University of Warwick and Institute of Advanced
Study for Early Career Fellowships. E.F. and M.I.G. acknowl-
edge EPSRC (EP/M027503/1) for supporting JH with a
Training Fellowship. E.F., M.I.G., and C.G. acknowledge the
Antimicrobial Resistance Cross Council Initiative, support by
BBSRC and MRC (MR/N006917/1).
■ REFERENCES
(1) Wise, R.; Carrs, O.; Cassell, G.; Fishman, N.; Guidos, R.; Levy, S.;
Powers, J.; Norrby, R.; Tillotson, G.; Davies, R.; Projan, S.; Dawson,
M.; Monnet, D.; Keogh-Brown, M.; Hand, K.; Garner, S.; Findlay, D.;
Morel, C.; Wise, R.; Bax, R.; Burke, F.; Chopra, I.; Czaplewski, L.;
Finch, R.; Livermore, D.; Piddock, L. J. V.; White, T. J. Antimicrob.
Chemother. 2011, 66 (9), 1939−1940.
(2) Centre for Disease Control; Antibiotic/Antimicrobial Resistance,
https://www.cdc.gov/drugresistance/.
(3) World Economic Forum; Global Risks, 2013; http://reports.
weforum.org/global-risks-2013/.
(4) Nathan, C. Nature 2004, 431 (7011), 899−902.
(5) O’Neil, J. The Review on Antimicrobial Resistance; O’Neil
Report.
(6) Richards, S.-J.; Jones, M. W.; Hunaban, M.; Haddleton, D. M.;
Gibson, M. I. Angew. Chem., Int. Ed. 2012, 51 (31), 7812−7816.
(7) Otten, L.; Gibson, M. I. RSC Adv. 2015, 5 (66), 53911−53914.
(8) Otten, L.; Fullam, E.; Gibson, M. I. Mol. BioSyst. 2016, 12 (2),
341−344.
(9) Andersson, D. I.; Hughes, D. Nat. Rev. Microbiol. 2010, 8 (4),
260.
(10) The Lancet; Elsevier, April 27, 2013; p 1431.
(11) World Health Organisation; AMR Factsheet 194, 2015.
(12) Makarov, V.; Manina, G.; Mikusova, K.; Möllmann, U.;
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